NBW Capital LLC Buys 857 Shares of Danaher Co. (NYSE:DHR)

NBW Capital LLC grew its stake in Danaher Co. (NYSE:DHR) by 3.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,864 shares of the conglomerate’s stock after purchasing an additional 857 shares during the period. NBW Capital LLC’s holdings in Danaher were worth $5,521,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Fairfield Bush & CO. increased its holdings in Danaher by 10.9% during the 1st quarter. Fairfield Bush & CO. now owns 4,840 shares of the conglomerate’s stock worth $1,420,000 after purchasing an additional 475 shares during the period. Zions Bancorporation N.A. increased its holdings in shares of Danaher by 19.3% in the 1st quarter. Zions Bancorporation N.A. now owns 2,468 shares of the conglomerate’s stock valued at $724,000 after acquiring an additional 400 shares during the period. Covestor Ltd increased its holdings in shares of Danaher by 76.8% in the 1st quarter. Covestor Ltd now owns 495 shares of the conglomerate’s stock valued at $145,000 after acquiring an additional 215 shares during the period. NewEdge Advisors LLC increased its holdings in shares of Danaher by 14.1% in the 1st quarter. NewEdge Advisors LLC now owns 31,530 shares of the conglomerate’s stock valued at $9,248,000 after acquiring an additional 3,897 shares during the period. Finally, Bridgewater Associates LP increased its holdings in shares of Danaher by 135.9% in the 1st quarter. Bridgewater Associates LP now owns 35,270 shares of the conglomerate’s stock valued at $10,346,000 after acquiring an additional 20,320 shares during the period. 79.05% of the stock is owned by institutional investors.

Insider Activity at Danaher

In related news, Director Teri List sold 3,289 shares of Danaher stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Teri List sold 3,289 shares of Danaher stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock worth $8,265,802 in the last 90 days. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock traded down $2.69 on Thursday, hitting $236.70. The company had a trading volume of 2,452,945 shares, compared to its average volume of 2,703,000. The firm has a market cap of $175.29 billion, a P/E ratio of 37.46, a price-to-earnings-growth ratio of 3.65 and a beta of 0.83. The company has a 50-day moving average price of $249.28 and a 200-day moving average price of $229.86. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.18. The business had revenue of $6.41 billion during the quarter, compared to analysts’ expectations of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The company’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.87 EPS. As a group, equities research analysts predict that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. The ex-dividend date of this dividend is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is currently 16.90%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Royal Bank of Canada lifted their price target on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. JPMorgan Chase & Co. boosted their target price on Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 20th. Barclays boosted their target price on Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 10th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, HSBC upgraded Danaher from a “hold” rating to a “buy” rating and boosted their target price for the stock from $250.00 to $280.00 in a research note on Wednesday. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $268.27.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.